Key statistics
On Monday, Iovance Biotherapeutics Inc (0JDK:LSE) closed at 3.66, 1.81% above its 52-week low of 3.59, set on Mar 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 3.66 |
Low | 3.66 |
Bid | -- |
Offer | -- |
Previous close | 3.79 |
Average volume | 96.78k |
---|---|
Shares outstanding | 327.88m |
Free float | 299.19m |
P/E (TTM) | -- |
Market cap | 1.23bn USD |
EPS (TTM) | -1.30 USD |
Data delayed at least 20 minutes, as of Mar 10 2025 19:06 BST.
More ▼
Announcements
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
- Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
More ▼